Copenhagen Q4: 12 Stocks That Moved the Market
The Q4 2025 earnings season in Copenhagen was marked by a market downturn, with the OMXC25 index falling 11.89% (January 8 – March 9). The results were characterized by stark contrasts: several companies showed strong growth, while others were overshadowed by one-off costs and disappointing forecasts, reflecting broader economic uncertainty.
Results: Operating profit fell by 68.1% and net profit turned negative. Revenue remained stable, declining by only 0.8%. Reasons: The profit decline was caused by a large DKK 298 million impairment of intangible assets. Without this, core operating profit would have been stable. The company issued a positive forecast for 2026. Market Reaction: The stock fell 6.3% on the day of the results but has since recovered slightly. The total decline since the announcement remains at 4.4%.
Results: Operating profit fell by 16.2% and net profit by 26.0%. The company also announced a significant dividend cut. Reasons: The main reason for the decline was a complete halt in the sale of next-generation products in North America and a decrease in sales of handmade cigars. Market Reaction: The market reacted extremely negatively to the news. Although the initial reaction was modest, the stock plummeted in the following days and has fallen nearly 34% since the results were released.
Results: Operating profit grew exceptionally by 186.5%, and net profit soared by 301.0%. Revenue increased by 13.2%. Reasons: The growth was driven by revenue from palm oil products, supported in particular by a 37% increase in the average selling price of palm kernels. The company's profitability also improved due to a reduction in operating expenses. Market Reaction: The stock reacted modestly to the results, rising only 0.3%. Since then, the share has remained stable, showing a slight increase of 1.1%.
Results: Operating profit grew by 9.4% and revenue by 5.7%. The company provided a strong growth forecast for 2026 and raised its dividend. Reasons: The main driver of growth was a 10% increase in sales volumes in the Western Europe segment. Market Reaction: Despite the positive results and forecast, the stock has been under selling pressure, falling 8.1% since the announcement. This suggests possible profit-taking after a previous rally.
Results: According to the report, the bank fell into a loss, with operating profit declining by 115.6%. However, net income grew strongly by 25.5%. Reasons: The loss was caused by a large one-off cost of DKK 942 million related to the merger of several banks. The core business showed strength. The bank also announced a major share buyback program. Market Reaction: The stock jumped 5.0% on the day of the results as investors focused on the strong core business. However, the share has since given back its gains and is now slightly below its pre-earnings level.
Results: Operating profit fell by 20.0%, and sales revenue decreased by 4.8%. Reasons: Profitability was pressured by increased raw material costs and depreciation related to investments. However, shortly after the results, the company announced its largest contract in history. Market Reaction: The stock rose 4.9% on the day of the results and has remained stable since. Investor sentiment was likely boosted by the new record contract, which overshadowed the weaker quarter.
Results: Operating profit growth slowed to 6.3%, while revenue continued to grow strongly at 11.9%. Reasons: The strong sales revenue growth was hampered by a faster increase in production costs (12.2%), which reduced profit margins. This is a common concern in the construction sector. Market Reaction: The stock fell 4.1% on the day of the results and has continued to decline, now trading 7.4% below its pre-earnings level.
Results: The company delivered an impressive performance, with operating profit growth accelerating to 88.8% and net profit increasing by 56.5%. Reasons: Growth was driven by a strong 14.5% sales increase in allergy tablets and the successful launch of the new drug, neffy®. Market Reaction: The initial reaction was surprisingly muted, with the stock falling 2.5%. However, it has since recovered and is now showing a slight 1.2% gain compared to its pre-earnings level.
Results: The company reported a sharp decline in operating profit, turning to a loss. Reasons: The loss was mainly due to high costs associated with the acquisition of an unprofitable Turkish company. However, management presented a restructuring plan and gave an optimistic forecast for 2026. Market Reaction: The market ignored the current loss and focused on future plans. The stock jumped 6.1% on the day of the results and has remained at a higher level since.
Results: The operating loss widened by an expected 27.9% as the company invests heavily in product development. However, the growth of the loss had slowed. Reasons: The loss was driven by research and development costs related to the development of anti-obesity drugs. Market Reaction: The stock fell 3.4% on the day of the results. However, disappointing clinical trial data released after the earnings report caused the stock to freefall, and it has now dropped by over 40%.
Results: Operating profit grew strongly by 47.7%, but net profit turned to a loss. Reasons: The growth in operating profit was supported by successful cost-cutting and a one-off gain from a property sale. The net loss was related to other accounting factors. Market Reaction: The stock fell 3.6% on the day of the results and has declined further since, now trading nearly 10% lower. Investors likely took profits after the stock's previous strong rally.
Results: Operating profit fell sharply by 81.3%. However, sales revenue grew steadily by 14.6%. Reasons: The profit decline was caused by large one-off investments in product development and costs related to a company acquisition. Core business sales revenue remained strong. Market Reaction: The stock rose 4.4% on the day of the results but has since fallen and is now trading 7.6% below its pre-earnings level, reflecting concerns about the high costs.
Conclusion
Copenhagen's Q4 earnings season was complex and multifaceted, as reflected by the sharp decline in the market index. Several broader themes emerged.
First, the results of many companies (SCHO, ALSYDB, GMAB, FLS) were distorted by large one-off costs or gains. This made a superficial analysis misleading and required investors to delve deeper into the health of the companies' core operations.
Second, the market proved to be forward-looking on several occasions. In the cases of both DFDS and AL Sydbank, current losses were ignored, and the market reacted positively to restructuring plans or strong underlying growth.
Third, there were stark contrasts within sectors. In healthcare, we saw both ALK-Abelló's impressive growth and Zealand Pharma's dramatic fall due to clinical trial results. This highlights the high potential and risks of the biotechnology field.
In summary, the season was jittery. Even several positive results failed to provide lasting support for stock prices, indicating investor caution. In the next season, all eyes will be on whether growth forecasts hold up in an uncertain economic environment.
RYTM content is for informational purposes only, not financial advice or recommendations. You are solely responsible for your investment decisions. Always consult a professional.